NCT06027554 · Phase 2 · RECRUITING
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
This trial is testing MitoQ, a mitochondria-targeted antioxidant supplement, in older adults aged 65 to 80 who have slow walking speed and/or mild cognitive impairment. Researchers want to see whether MitoQ improves blood vessel function in the brain and body, physical mobility, and cognitive performance. It is a Phase 2 trial, meaning researchers are exploring whether it works and is safe — it is not a proven or approved treatment.
You may qualify if
- men and women aged 65-80 with a slow gait speed (0.4m/s based on a 4m walk) and/or mild cognitive impairment.
- good cardiovascular health (not taking any blood pressure/flow/metabolism altering medications)
You're excluded if
- A vaccination in past two weeks
- Recent acute infection three weeks prior to enrollment
- Known immunodeficiency (including HIV infection, primary immunodeficiency, any history of chemotherapy or radiotherapy
- Use of medicines during past 6 months known to alter immune response such as high- dose corticosteroids
- Severe autoimmune disease requiring biological therapy
- Major severe illness and/or Hospitalization in past 3 months
- On warfarin or other medications that are considered a blood thinner
- Recent fall or other conditions that will impair ability to complete and/or interpret mobility performance test
- Known bleeding disorder
- Any conditions that would impair the function to perform grip strength test
- include advanced neurological disease, severe co-morbid disease, terminal illness with reduced life expectancy, severe disability, unintentional weight loss in last 12 months and participation in another study.
- Diabetes patients requiring insulin (For reducing the risk that participants will have hypoglycemic episodes when fasting for study visits)
- Baseline ECG QTc >450 ms in men and QTc >460 ms in women
- Prior diagnosis of ventricular arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-01-09